Brachytherapy

Brachytherapy is an internal radiation treatment in which sealed radioactive sources are positioned inside or next to a tumor. Its defining advantages are high dose concentration, treatment precision, and the ability to limit exposure to nearby healthy tissue. Clinical use spans several cancers, including cervical, prostate, breast, skin, and selected gynecological, lung, and head-and-neck tumors. Adoption is shaped by clinical evidence, treatment guidelines, radiation-safety requirements, specialist availability, reimbursement, and access to imaging and afterloading infrastructure.

The field is moving toward image-guided and adaptive procedures that use ultrasound, computed tomography, magnetic resonance imaging, and three-dimensional treatment planning to improve applicator placement and dose conformity. High-dose-rate afterloading supports controlled source delivery and can reduce staff exposure compared with manual techniques, while low-dose-rate and pulsed-dose-rate approaches remain relevant for selected indications. Increasing emphasis on organ preservation, outpatient workflows, multidisciplinary care, and patient-specific planning is also changing service design. Persistent barriers include procedure complexity, operating-room coordination, quality assurance, and uneven access to trained teams.

Artificial intelligence can support contouring, applicator reconstruction, image registration, treatment-plan optimization, quality checks, and workflow prioritization. These capabilities may reduce repetitive planning tasks and help clinicians identify inconsistencies across imaging, documentation, and dose constraints. However, safe implementation requires representative validation data, transparent performance monitoring, cybersecurity controls, interoperability with treatment-planning systems, and clinician oversight. AI should assist-not replace-radiation oncologists, medical physicists, dosimetrists, and technologists, particularly when anatomy is distorted or evidence is limited.

North America benefits from established radiation-oncology infrastructure, advanced imaging, and relatively broad access to specialized centers, while reimbursement complexity and workforce constraints influence adoption. Europe combines mature clinical practice with strong guideline and quality-assurance traditions, but access varies across health systems. Asia-Pacific includes highly capable centers alongside substantial rural and workforce gaps; cervical-cancer control and expanding cancer services remain important priorities. Latin America is advancing through tertiary hospitals and public-health programs, although equipment availability and referral delays remain challenges. The Middle East is investing in specialized oncology capacity, with concentration in major urban centers. Africa faces the greatest infrastructure and workforce constraints, making reliable equipment, training, maintenance, and integration with comprehensive cancer care central to progress.

ASEAN countries show varied levels of oncology infrastructure, creating opportunities for regional training, referral networks, and common quality practices. BRICS members combine large patient populations with significant differences in public and private capacity, making affordability, domestic workforce development, and technology maintenance important themes. The European Union benefits from cross-border research and harmonized regulatory principles, while national reimbursement and service organization remain diverse. G7 health systems generally have strong specialist capabilities but must address aging populations, staffing pressure, and sustainable delivery models. GCC countries are expanding advanced cancer services and specialist capacity, often through centralized centers. NATO members span mature and developing systems, so resilience, supply continuity, emergency preparedness, and interoperable clinical standards are relevant shared considerations.

Australia combines advanced cancer centers with geographic access challenges. Brazil’s large and varied health system makes regional referral pathways and public-sector capacity important. Canada has strong specialist expertise, while distance and provincial organization affect access. China is expanding sophisticated oncology services alongside substantial regional variation. France, Germany, Italy, Spain, and the United Kingdom have established radiation-oncology capabilities, with differences in reimbursement, procurement, workforce, and waiting-time management. India has leading urban centers but marked disparities in equipment and specialist availability. Japan and South Korea support technologically advanced care, with aging-population needs shaping service planning. Mexico is strengthening oncology infrastructure while facing access and referral challenges. Russia’s capabilities vary by region, and continuity of equipment, training, and maintenance is important. In the United States, advanced image guidance and multidisciplinary care are widely available in major centers, while affordability, workforce distribution, and rural access remain significant considerations.

Industry and health-system leaders should prioritize evidence-based indications, multidisciplinary governance, and standardized quality assurance across imaging, applicator placement, source handling, planning, and follow-up. Investment decisions should account for the complete care pathway, including trained personnel, service contracts, backup capacity, radiation safety, and integration with oncology information systems. Leaders should develop regional referral networks and structured training programs to extend specialist expertise beyond major centers. AI pilots should begin with clearly defined clinical tasks, prospective validation, auditability, and human review. Patient-centered measures-including treatment burden, functional outcomes, communication, and equitable access-should complement technical dose metrics when evaluating service performance.

This executive summary uses a qualitative synthesis framework focused on established clinical practice, technology adoption factors, health-system conditions, and implementation barriers. The assessment organizes evidence by treatment modality, imaging and planning workflow, workforce, infrastructure, safety, regulation, reimbursement, and access. Regional, group, and country observations are presented as contextual comparisons rather than quantitative rankings. Claims should be validated against current clinical guidelines, peer-reviewed studies, regulatory publications, health-system data, and facility-level assessments before informing procurement, policy, or clinical decisions. No market estimates, market shares, forecasts, or company-specific conclusions are included.

Brachytherapy remains a highly specialized treatment whose value depends on accurate patient selection, precise imaging and planning, safe source delivery, and coordinated multidisciplinary execution. Image guidance, adaptive workflows, and carefully governed AI can improve consistency and efficiency, but technology alone cannot overcome shortages in trained staff, maintenance, referral capacity, or reimbursement support. Sustainable progress will therefore require integrated investment in people, equipment, quality systems, evidence generation, and equitable access across regions and health systems.